37508 Federal Register / Vol. 83, No. 148 / Wednesday, August 1, 2018 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine Drug 

Testing for Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). 

A notice listing all currently HHScertified laboratories and IITFs is 

published in the Federal Register 

during the first week of each month. If 

any laboratory or IITF certification is 

suspended or revoked, the laboratory or 

IITF will be omitted from subsequent 

lists until such time as it is restored to 

full certification under the Mandatory 

Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at http://www.samhsa.gov/ 

workplace. 

FOR FURTHER INFORMATION CONTACT: 

Charles LoDico, Division of Workplace 

Programs, SAMHSA/CSAP, 5600 

Fishers Lane, Room 16N02C, Rockville, 

Maryland 20857; 240–276–2600 (voice). 

SUPPLEMENTARY INFORMATION: The 

Department of Health and Human 

Services (HHS) notifies federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITF) currently 

certified to meet the standards of the 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines). The Mandatory 

Guidelines were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs,’’ as amended in the 

revisions listed above, requires strict 

standards that laboratories and IITFs 

must meet in order to conduct drug and 

specimen validity tests on urine 

specimens for federal agencies. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that it has met minimum standards. 

In accordance with the Mandatory 

Guidelines dated January 23, 2017 (82 

FR 7920), the following HHS-certified 

laboratories and IITFs meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

HHS-Certified Instrumented Initial 

Testing Facilities 

Dynacare, 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190, (Formerly: GammaDynacare Medical Laboratories). 

HHS-Certified Laboratories 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

844–486–9226. 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823, (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.). 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130, (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS, 66215– 

2802, 800–445–6917. 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890. 

Dynacare*, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630, (Formerly: GammaDynacare Medical Laboratories). 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609. 

Laboratory Corporation of America 

Holdings, 7207 N Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845, 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.). 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

Legacy Laboratory Services—MetroLab, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. Testing for Veterans Affairs 

(VA) Employees Only. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774, (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 


sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 148 / Wednesday, August 1, 2018 / Notices 37509 

1The figures provided in this notice may be 

rounded for publication purposes only. The 

calculations for the adjusted fees and limitations 

were made using unrounded figures, unless 

otherwise noted. 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 15175 Innovation 

Drive, San Diego, CA 92128, 888– 

635–5840. 

Quest Diagnostics Incorporated, 1777 

Montreal Circle, Tucker, GA 30084, 

800–729–6432, (Formerly: SmithKline 

Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Redwood Toxicology Laboratory, 3700 

Westwind Blvd., Santa Rosa, CA 

95403, 800–255–2159. 

STERLING Reference Laboratories, 2617 

East L Street, Tacoma, WA 98421, 

800–442–0438. 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085, Testing for 

Department of Defense (DoD) 

Employees Only. 

* The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on January 23, 2017 (82 FR 

7920). After receiving DOT certification, 

the laboratory will be included in the 

monthly list of HHS-certified 

laboratories and participate in the NLCP 

certification maintenance program. 

Charles P. LoDico, 

Chemist. 

[FR Doc. 2018–16440 Filed 7–31–18; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

[CBP Dec. 18–08] 

COBRA Fees To Be Adjusted for 

Inflation in Fiscal Year 2019 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: General notice. 

SUMMARY: This document announces 

that U.S. Customs and Border Protection 

(CBP) is adjusting certain customs user 

fees and limitations established by the 

Consolidated Omnibus Budget 

Reconciliation Act (COBRA) for Fiscal 

Year 2019 in accordance with the Fixing 

America’s Surface Transportation Act 

(FAST Act) as implemented by CBP 

regulations. 

DATES: The adjusted amounts of 

customs COBRA user fees and their 

corresponding limitations set forth in 

this notice for Fiscal Year 2019 are 

required as of October 1, 2018. 

FOR FURTHER INFORMATION CONTACT: Tina 

Ghiladi, Director—Office of Finance, 

202–344–3722, UserFeeNotices@

cbp.dhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

On December 4, 2015, the Fixing 

America’s Surface Transportation Act 

(FAST Act, Pub. L. 114–94) was signed 

into law. Section 32201 of the FAST Act 

amended section 13031 of the 

Consolidated Omnibus Budget 

Reconciliation Act (COBRA) of 1985 (19 

U.S.C. 58c) by requiring certain customs 

COBRA user fees and corresponding 

limitations to be adjusted by the 

Secretary of the Treasury (Secretary) to 

reflect certain increases in inflation. 

Sections 24.22 and 24.23 of title 19 of 

the Code of Federal Regulations (19 CFR 

24.22 and 24.23) describe the 

procedures that implement the 

requirements of the FAST Act. 

Specifically, paragraph (k) in section 

24.22 (19 CFR 24.22(k)) sets forth the 

methodology to determine the change in 

inflation as well as the factor by which 

the fees and limitations will be adjusted, 

if necessary. The fees and limitations 

subject to adjustment, which are set 

forth in Appendix A and Appendix B of 

part 24, include the commercial vessel 

arrival fees, commercial truck arrival 

fees, railroad car arrival fees, private 

vessel arrival fees, private aircraft 

arrival fees, commercial aircraft and 

vessel passenger arrival fees, dutiable 

mail fees, customs broker permit user 

fees, barges and other bulk carriers 

arrival fees, and merchandise processing 

fees, as well as the corresponding 

limitations. 

Determination of Whether an 

Adjustment Is Necessary for Fiscal Year 

2019 

In accordance with 19 CFR 24.22, CBP 

must determine annually whether the 

fees and limitations must be adjusted to 

reflect inflation. For fiscal year 2019, 

CBP is making this determination by 

comparing the average of the Consumer 

Price Index—All Urban Consumers, U.S. 

All items, 1982–84 (CPI–U) for the 

current year (June 2017–May 2018) with 

the average of the CPI–U for the 

comparison year (June 2016-May 2017) 

to determine the change in inflation, if 

any. If there is an increase in the CPI of 

greater than one (1) percent, CBP must 

adjust the customs COBRA user fees and 

corresponding limitations using the 

methodology set forth in 19 CFR 

24.22(k). (19 CFR 24.22(k)). Following 

the steps provided in paragraph (k)(2) of 

section 24.22, CBP has determined that 

the increase in the CPI between the most 

recent June to May 12-month period 

(June 2017–May 2018) and the 

comparison year (June 2016-May 2017) 

is 2.063 1 percent. As the increase in the 

CPI is greater than one (1) percent, the 

customs COBRA user fees and 

corresponding limitations must be 

adjusted for Fiscal Year 2019. 

Determination of the Adjusted Fees and 

Limitations 

Using the methodology set forth in 

section 24.22(k)(2) of the CBP 

regulations (19 CFR 24.22(k)), CBP has 

determined that the factor by which the 

base fees and limitations will be 

adjusted is 4.866 percent (base fees and 

limitations can be found in Appendix A 

and B to part 24 of title 19). In reaching 

this determination, CBP calculated the 

values for each variable found in 

paragraph (k) of 19 CFR 24.22 as 

follows: 

• The arithmetic average of the CPI– 

U for June 2017–May 2018, referred to 

as (A) in the CBP regulations, is 

247.540; 

• The arithmetic average of the CPI– 

U for Fiscal Year 2014, referred to as (B), 

is 236.009; 

• The arithmetic average of the CPI– 

U for the comparison year, referred to as 

(C), is 242.328; 

• The difference between the 

arithmetic averages of the CPI–U of the 


sradovich on DSK3GMQ082PROD with NOTICES